The biological and clinical parameters of the patients at the time of cHL diagnosis as well as the parameters of interim PET status and progressive or primary refractory disease were analyzed in relation to the levels of GATA3 expression. This evidence concerns the gene GATA3 and classic Hodgkin lymphoma.